Part of stockport exploration, inc.
Sona Nanotech Inc is engaged in researching and developing gold nanorod products. It makes products for diagnostic tests and medical treatment applications. The company's product includes Gemini and Saliva tests.
Clinical Trials
4
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2014
Completed
1
25.0%
Not yet recruiting
2
50.0%
Terminated
1
25.0%
No approval data available
- Sona Nanotech's Targeted Hyperthermia Therapy combined with immunotherapy achieved 38% tumor clearance in a preclinical colorectal cancer study published in the Journal of Nanobiotechnology. - The combination protocol cleared tumors in immunologically "cold" colorectal cancer models within 24 days, with animals remaining disease-free for 45 days. - This marks the third cancer type where Sona has demonstrated immune activation with THT, following previous success in melanoma patients with an 80% clinical response rate. - The company plans to use these findings to inform protocols for upcoming clinical studies targeting immunotherapy-resistant cancers.
- Sona Nanotech's targeted hyperthermia therapy demonstrated an 80% response rate in a first-in-human study of 10 patients with immunotherapy-resistant cutaneous metastatic melanoma. - Six out of eight responding patients showed complete tumor elimination confirmed by biopsy within two weeks of treatment, with no detectable residual melanoma. - The therapy uses gold nanorods heated by infrared laser to 45°C, selectively killing cancer cells while preserving healthy tissue and stimulating immune response. - The company has applied for Health Canada approval to advance to a Canadian clinical trial, marking its transition from preclinical to clinical-stage development.
- Sona Nanotech has successfully completed bacterial endotoxin testing on its biocompatible gold nanorods, with all samples showing endotoxin levels below detection limits. - The tested gold nanorods will be used in Sona's upcoming first-in-human Early Feasibility study for its Targeted Hyperthermia™ cancer therapy, with patient enrollment expected this summer. - Sona's proprietary CTAB-free gold nanorods eliminate toxicity risks associated with conventional gold nanorod technologies, potentially offering a safer approach for photothermal cancer treatment.
- BioVaxys Technology and Sona Nanotech have formed a research collaboration to develop innovative cancer therapeutics by combining BioVaxys' DPX immune educating platform with Sona's targeted hyperthermia therapy using gold nanorods. - The joint research will evaluate the immune-stimulatory properties of DPX administered with photothermal cancer therapy, as well as explore DPX as a carrier for neoantigens expressed on tumor cell surfaces following immunotherapy. - Studies will be conducted at Dalhousie University under Sona's CMO Dr. Carman Giacomantonio, with both companies sharing ownership of any novel therapeutic candidates developed through the program.
- Sona Nanotech's innovative Targeted Hyperthermia therapy, utilizing biocompatible gold nanorods, demonstrates effectiveness in treating immunogenically 'cold' tumors through controlled heat delivery. - The groundbreaking research will be showcased at the 19th Canadian Melanoma Conference in Vancouver, featuring presentations by the company's Chief Medical Officer and research team. - The therapy works by using infrared light to heat gold nanorods to 42-48°C, potentially enhancing immune response and improving drug delivery while maintaining safety and cost-effectiveness.
